Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real world study comparing ixazomib, lenalidomide and dexamethasone (IRD) triplet and lenalidomide and dexamethasone (Rd) doublet in patients with relapsed and/or refractory multiple myeloma (RRMM)

Next Previous
Trial Profile

Real world study comparing ixazomib, lenalidomide and dexamethasone (IRD) triplet and lenalidomide and dexamethasone (Rd) doublet in patients with relapsed and/or refractory multiple myeloma (RRMM)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 14 Dec 2021 Results of updated analysis assessing the overall survival (OS) and the PFS2, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
  • 17 Jun 2021 Results of extended subgroup analysis assessing the effect of Ixazomib, Lenalidomide and Dexamethasone in routine practice, presented at the 26th Congress of the European Haematology Association
  • 16 Dec 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top